A study comparing ECG parameters at baseline and after 4–12 weeks in patients with stage III–IV malignant melanoma treated with either nivolumab monotherapy or combination therapy with nivolumab and ipilimumab (an anti-CTLA-4 agent) reported a significant increase in QTd in the combination therapy group. The gene discussed is CTLA4; the disease is melanoma.